# A Post-Authorisation Safety Study (PASS) of Patients Treated With Lonapegsomatropin

> **NCT05775523** · — · RECRUITING · sponsor: **Ascendis Pharma Endocrinology Division A/S** · enrollment: 500 (estimated)

## Conditions studied

- Growth Hormone Deficiency

## Interventions

- **DRUG:** No intervention

## Key facts

- **NCT ID:** NCT05775523
- **Lead sponsor:** Ascendis Pharma Endocrinology Division A/S
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2023-03-20
- **Primary completion:** 2033-03
- **Final completion:** 2033-03
- **Target enrollment:** 500 (ESTIMATED)
- **Last updated:** 2026-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05775523

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05775523, "A Post-Authorisation Safety Study (PASS) of Patients Treated With Lonapegsomatropin". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05775523. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*